Senior Director, Program Team Lead

About   Iovance Biotherapeutics, Inc.   Iovance Biotherapeutics , Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The  Iovance TIL platform  spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit  www.iovance.com . Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on  www.iovance.com . Overview The Senior Director, Program Team Lead owns integrated program strategy for one or more TIL cell therapy assets across early-to-late-stage clinical development. This role connects clinical, CMC, regulatory, and commercial workstreams into a single plan that maximizes clinical probability of success, regulatory approval, and commercial value, all within the context of Iovance's broader portfolio strategy. The Program Team Lead chairs the cross-functional program team, manages timelines across workstreams, and is the central point of accountability for translating strategy into execution. This individual partners with senior leadership to advance programs from early clinical studies through pivotal trials, global regulatory submissions, and into commercial planning. The right candidate brings deep oncology development and CMC experience with the judgment to navigate autologous cell therapy. They are as comfortable shaping an early-stage data strategy as they are driving late-stage registration execution, and they ensure every program decision maintains a clear line of sight to clinical success, regulatory approval, and commercial differentiation. Essential Functions and Responsibilities Program Strategy • Own the program strategy and vision from early development through registration and commercialization, ensuring alignment with Iovance's TIL platform strategy. • Frame program decisions around clinical probability of success, regulatory path, and commercial value. • Develop and present strategic options and trade-off analyses to senior leadership and governance bodies. • Track the competitive landscape in solid tumor oncology and cell therapy; translate insights into program-level actions. Cross-Functional Execution • Work to align SME deliverables with overall development strategy, anticipating risks, proposing alternative scenarios and working with the cross functional team to drive accountability. • Partner with the Program Manager to align domain area strategy & execution plans with asset level strategy across all functions, including Clinical, Regulatory, Commercial and CMC. • Own program dashboards/reporting that keeps leadership informed on program status, timelines, strategic roadmap progress, upcoming inflection points, and open risks. Governance and Stakeholder Management • Serve as the primary strat